Human antibody against aggrecanase-type ADAMTS species for therapeutics of aggrecanase-related diseases
First Claim
Patent Images
1. An antibody comprising a light chain variable region and a heavy chain variable region,wherein the light chain variable region comprises:
- CDR1 comprising the amino acid sequence of SEQ ID NO;
1;
CDR2 comprising the amino acid sequence of SEQ ID NO;
2; and
CDR3 comprising the amino acid sequence of SEQ ID NO;
3, andwherein the heavy chain variable region comprises;
CDR1 comprising the amino acid sequence of SEQ ID NO;
4;
CDR2 comprising the amino acid sequence of SEQ ID NO;
5; and
CDR3 comprising the amino acid sequence of SEQ ID NO;
6, wherein the antibody specifically binds human ADAMTS4.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides an antibody that specifically binds to human aggrecanase, and inhibits enzymatic activity of the human aggrecanase. In one embodiment, aggrecanase is ADAMTS4. In one embodiment, the antibody recognizes a particular epitope in human ADAMTS4, and inhibits not only aggrecanase activity of human ADAMTS4 but also aggrecanase activity of human ADAMTS5. In addition, the present invention also provides use of said antibody in the prophylaxis or treatment of the progression of arthritis.
-
Citations
7 Claims
-
1. An antibody comprising a light chain variable region and a heavy chain variable region,
wherein the light chain variable region comprises: - CDR1 comprising the amino acid sequence of SEQ ID NO;
1;
CDR2 comprising the amino acid sequence of SEQ ID NO;
2; and
CDR3 comprising the amino acid sequence of SEQ ID NO;
3, andwherein the heavy chain variable region comprises;
CDR1 comprising the amino acid sequence of SEQ ID NO;
4;
CDR2 comprising the amino acid sequence of SEQ ID NO;
5; and
CDR3 comprising the amino acid sequence of SEQ ID NO;
6, wherein the antibody specifically binds human ADAMTS4. - View Dependent Claims (2, 3, 4, 5, 6, 7)
- CDR1 comprising the amino acid sequence of SEQ ID NO;
Specification